IBM Surges on GenAI, Cloud; Amex Hikes Fees 02/03/26
/
RSS Feed
IBM Surges on GenAI, Cloud; Amex Hikes Fees 02/03/26
Key Stories:
- American Express, the prominent payments company, is making moves to solidify its premium market position, announcing plans to raise annual fees and enhance luxury benefits across its premium cards. The company is also tightening access rules for its exclusive Centurion Lounges, a strategy aimed at managing costs linked to premium rewards and lounge usage while directly competing with rivals like JPMorgan Chase for affluent and younger clientele. Investors will be keen to see how these adjustments affect customer loyalty and acquisition in the high-end credit card space. Read more
- Turning to the healthcare sector, analysts at Bank of America have given Johnson & Johnson, the global healthcare and pharmaceutical giant, a vote of confidence by lifting its price target to $227 from a previous $221. BofA maintained a Neutral rating on the shares of the often-cited low-volatility stock, indicating a perceived increase in fair value despite not recommending a strong ‘buy’ at current levels. This positive adjustment suggests analysts see some upside for JNJ in the near term. Read more
- In another look at the biopharma landscape, Citi has adjusted its outlook on AbbVie Inc., the research-based pharmaceutical company. The firm recently trimmed its price target on AbbVie to $230, down from $235, while keeping a Neutral rating on the stock. This price target cut was part of broader adjustments within the biopharma group, signaling that analysts are recalibrating valuations across the sector. Shareholders should monitor the rationale behind these sector-wide revisions. Read more
- Looking ahead to a busy day on the corporate calendar, investors are bracing for a flurry of earnings reports scheduled for tomorrow, February 3rd. Among the companies set to release their results are tech giant Advanced Micro Devices, popular fast-casual chain Chipotle Mexican Grill, and pharmaceutical heavyweights Pfizer and Merck. Additionally, the Senate will hold a crucial hearing regarding Netflix’s proposed bid to acquire Warner Bros. Discovery. These events are poised to drive market activity and could introduce significant volatility, making these names ones to watch closely. Read more
- Wrapping up our market update, we have some positive news for International Business Machines, the technology and consulting giant. Argus recently boosted its price target on IBM to $360, up from $340, while reaffirming a strong Buy rating on the stock. The upgrade comes on the heels of IBM’s better-than-anticipated fourth-quarter performance, driven by strong momentum in its generative AI initiatives and hybrid cloud offerings. This analyst conviction suggests continued optimism regarding IBM’s strategic shift and its ability to capitalize on emerging tech trends. Read more
Keywords: ABBV, AMD, AXP, AbbVie, American Express, Argus, BofA, Buy rating, CMG, Centurion Lounge, Citi, GenAI, IBM, International Business Machines, JNJ, Johnson & Johnson, MRK, NFLX, PFE, Q4 earnings, Senate hearing, WBD, acquisitions, analyst rating, annual fees, biopharma, consumer discretionary, consumer finance, credit cards, earnings, entertainment, financial services, healthcare, hybrid cloud, low volatility, pharma, pharmaceuticals, premium cards, price target, tech, technology